Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR447971 first-in-human study in hidradenitis
NL-OMON61148Phase 1Recruiting
- Sponsor
- Sanofi
- Start
- May 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of KT-485 in hidradenitis suppurativa (HS), sponsored by Sanofi. Primary endpoint: Primary endpoint(s). Started May 2026; status: recruiting.
02
Drugs
KT-485
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON61148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61148.